Back to overview
Active

Oxbryta Liver Injury Lawsuit

Oxbryta (Voxelotor) was designed to treat complications associated with sickle cell disease. However, users allege that the medication has caused serious side effects, including liver injury and gastrointestinal issues.

Last updated May 25, 2026

2 primary sources
N/A+

ACTIVE CASES

$1M+

TOP ESTIMATE

High

RISK OF DAMAGE

1-3 yr*

STATUTE WINDOW

 Search

OVERVIEW

Oxbryta Liver Injury Lawsuit Overview

What is Oxbryta?

Oxbryta (Voxelotor) is a medication used to treat sickle cell disease. It helps improve oxygen delivery to cells by enhancing hemoglobin function.

Link to Liver Damage

Post-approval studies have shown that Oxbryta use for sickle cell disease (SCD) can cause liver injury, along with other issues such as arthritis, gastrointestinal problems, and more.

Manufacturer's Liability

Plaintiffs allege that Pfizer is responsible for design defects, failure to warn, negligence, and false advertising related to Oxbryta.

Who is eligible?

Individuals who used Oxbryta and experienced a decline in health after its use may be eligible.

CLAIMS IN AMERICA

The Complete Oxbryta Liver Injury Lawsuit Guide

2026 EDITION

FREE PDF • 47 PAGES

The Complete Oxbryta Liver Injury Lawsuit Lawsuit Guide

Everything you need to know about the Oxbryta litigation, including reported risks and how claims are being evaluated in U.S. courts.

Case background and medical findings
How to understand eligibility and documentation
What medical records are relevant
How legal fees and contingency arrangements work
No sign-up required
Search

LITIGATION PROGRESS

Oxbryta Liver Injury Lawsuit Timeline

April 2026

The parties involved in Oxbryta lawsuits have requested an extension from the judge to finalize the settlement terms.

March 2026

Individuals impacted by Oxbryta complications have asked for a delay in the upcoming status hearing.

January 2026

A patient, along with several other plaintiffs in the class action lawsuit, has requested an additional 60 days to continue settlement negotiations.

2025

Retired Judge Philip S. Gutierrez was appointed by the presiding judge to facilitate mediation and settlement discussions in the Oxbryta cases.

 Search

Estimated Payout

What Affects Your Claim

1

Type of Injury

Specific injuries caused by Oxbryta use, such as liver damage, gastrointestinal issues, or other related complications.

2

Medical Documentation

The medical records, including diagnosis dates, treatment history, and lab results, which help establish the connection between Oxbryta use and the reported injury.

3

Timing and Evidence

The timeline of when the injury occurred in relation to Oxbryta use, and the supporting evidence that strengthens your claim, such as prescriptions and medical consultations.

*Claim outcomes depend on diagnosis, timing, and medical records. Similar cases may be valued differently based on each person’s circumstances.

Diagnostic Resources

Find a lab nearby

Locate certified MRI and neurology imaging centers to obtain the diagnostic records needed to support your claim.

Filter:
0 results near Chicago
sorted by distance
check

What to request : Ask for a contrast-enhanced brain MRI specifically looking for meningioma. Request both the radiologist's report and the imaging CD both are needed for your legal claim.

 Search

The process

How it works

From submission to attorney match, every case follows the same four-step review.

01
2 min

Submit your case

Answer a short questionnaire about Oxbryta use and diagnosis.

02
2 hours

Initial review

A specialist reviews your submission and checks eligibility.

03
24 hours

Case manager call

You may be contacted to discuss medical history and records.

04
72 hours

Attorney match

If eligible, your case may be referred to a lawyer handling similar claim.

Free Case Evaluation

Check your eligibility today.

Estimated Range

$500K+

Start now
Free, no obligation
100% confidential
Takes ~3 minutes

Quick Facts

Defendant
Pfizer Inc.*
Drug
Voxoletor
Court
N/A
MDL
N/A
Cases filed
N/A
*Originally developed by Global Therapeutics Limited and later acquired by Pfizer in 2022.
Status
active

On This Page

Start now